| Literature DB >> 24263951 |
Abstract
In this issue of Blood, Zimmerman and colleagues demonstrate that the tyrosine kinase inhibitor (TKI) crenolanib effectively suppresses growth of leukemic cells harboring both FLT3-ITD and FLT3-TKD mutations, the latter of which are increasingly seen to emerge as resistant mutations after FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy.Entities:
Mesh：
Substances：
Year: 2013 PMID： 24263951 DOI： 10.1182/blood-2013-10-528992
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113